Pharmaceutical
    PRISM MarketView Features Q&A with Dr. Michael Chancellor: Lipella Pharmaceuticals Advances Innovative Treatments for Hemorrhagic Cystitis During Urology Awareness Month
    NEW YORK, September 25, 2024 - PRISM MediaWire - PRISM MarketView presents an exclusive Q&A with Dr. Michael Chancellor, Co-founder and Chief Medical Officer of Lipella Pharmaceuticals, Inc. (Nasdaq: LIPO). In this interview, Dr. Chancellor provides insights into the...

    25 September 2024

    read more...
    LIPOLipella PharmaceuticalsMedical ResearchHEALTHCAREpharmaceuticalNASDAQBiotechnologyNews ReleasePRISM MarketViewstock marketPRISM DigitalMediaPRISM MediaWirePress Release
    News
    Lipella Pharmaceuticals Reports Encouraging Early Tolerability Results in Phase 2a Trial of LP-310 for Oral Lichen Planus
    PITTSBURGH, Sept. 24, 2024 - PRISM MediaWire - Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on addressing serious diseases with significant unmet needs, today announced an update on its ongoing m...

    24 September 2024

    read more...
    Lipella PharmaceuticalsLIPOCancer TreatmentNASDAQHEALTHCAREpharmaceuticalBiotechnologyBiopharmaceuticalPress ReleaseNews ReleasePRISM DigitalMediaPRISM MarketViewPRISM MediaWirestock market
    News
    Halberd Partnership Secures Contract from Defense Atomics Corporation to Address Brain Injury and PTSD
    Contributing Funding and a Significant Additional Tool to Combat PTSD and TBI

    11 September 2024

    read more...
    HALBHalberd CorporationBiotechnologyBiopharmaceuticalHEALTHCAREWatchDawgOTCOTC MarketsNews ReleasePRISM DigitalMediaPRISM MarketViewbiotechstock marketPRISM MediaWirePress Release
    Biotechnology
    Aclarion Technology Advances Global Validation with First Nociscan Exams in LIFEHAB Trial on Low Back Pain
    New York, September 10, 2024 - PRISM MediaWire - Aclarion, Inc. (Nasdaq: ACON), a healthcare technology company focused on leveraging biomarkers and augmented intelligence to identify chronic low back pain, announced the completion of the first exams in its ongoing LIFEH...
    read more...
    News
    Halberd Corp. Issues Letter to Shareholders - Patented LDN+ Evolves into WatchDawg™ for Veteran Suicide Reduction
    Early Pilot Study Data from Veteran Volunteers is Compelling - Part B

    9 September 2024

    read more...
    News
    Aclarion Added to PRISM Emerging Medical Devices Index
    · Company's industry-first technology addresses chronic low back pain

    6 September 2024

    read more...
    News
    Healthy Longevity is One of Key Development Goals of ANEW’s Novel Gene Therapy
    Company will use novel, patented Klotho Gene (s-KL) in studies

    4 September 2024

    read more...
    News
    BioStem Technologies Inc. to Present at the H.C. Wainwright 26th Annual Global Investment Conference in New York on September 9th at 3:30 PM ET
    Advanced wound care MedTech company recently reported a record second-quarter with $116.4M in revenue for H1, 2024

    29 August 2024

    read more...
    News
    Lipella Pharmaceuticals to Participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York
    Company has two lead drug candidates for rare disease indications in IND approved phase 2 clinical trials using the 505(b)(2) pathway

    27 August 2024

    read more...
    News
    Halberd Corp. Issues Letter to Shareholders
    Jackson Center, PA, August 26, 2024 – PRISM MediaWire - Halberd Corporation (OTC PINK: HALB) today issued the following letter to its shareholders: 

    26 August 2024

    read more...
    1
    2
    3
    4
    5
    6
    7
    We use cookies to run our website, analyze your use of our services, manage your online preference & personalize ad content. By accepting our cookies, you’ll get relevant content and social media features, personalized ads, and an enhanced browsing experience. To manage your choices, click „Cookie Settings”. Necessary cookies are required for the core website functionality and cannot be rejected. For more information, see our Cookie Policy.
    Cookie settings
    Cookies used on the site are categorized and below you can read about each category and allow or deny some or all of them, except for Necessary Cookies which are required to provide core website functionality. When categories that have been previously allowed are disabled, all cookies assigned to that category will be removed from your browser. You can see a list of cookies assigned to each category and detailed information on those cookies in the “Cookie Policy” tab.
    Necessary cookies
    Some cookies are required to provide core functionality. The website won't function properly without these cookies and they are enabled by default and cannot be disabled.
    Preferences
    Preference cookies enables the website to remember information to customize how the website looks or behaves for each user. This may include storing selected currency region, language or color theme.
    Analytical cookies
    Analytical cookies help us improve our website by collecting and reporting information on its usage.
    Marketing cookies
    Marketing cookies are used to track visitors across websites to allow publishers to display relevant and engaging advertisements. By enabling marketing cookies, you grant permission for personalized advertising across various platforms.